From the 67th annual scientific sessions of the American Diabetes Association: Exenatide associated with sustained blood glucose control, weight loss after 3 years of treatment

News
Article

An open-label extension study of exenatide demonstrated sustained blood glucose control and weight loss in patients with type 2 diabetes.

Key Points

An open-label extension study of exenatide demonstrated sustained blood glucose control and weight loss in patients with type 2 diabetes, said John Buse, MD, chief, Division of General Medicine and Clinical Epidemiology, University of North Carolina, Chapel Hill.

Previously announced 2-year data collected during the extension phase of the trial demonstrated a –1.1% decrease in HbA1c levels and a –4.7-kg decline in body weight from baseline among patients randomized to exenatide. Both postprandial glucose and fasting plasma glucose levels were reduced with use of exenatide.

"Eighty-four percent of 3-year completers experienced weight reduction," Dr Buse said. "Sixty-eight percent both lost weight and had a reduction in [Hb]A1c."

A subgroup analysis demonstrated a 17% improvement in homeostasis model assessment-B (HOMA-B), a surrogate of beta-cell function, from baseline to 3 years, Dr. Buse said.

Recent Videos
Video 5 - "Obstacles in Adapting Diabetes Technology to Individual Needs" - 1 KOL is featured
Video 4 - "The Impact of Continuous Glucose Monitors & Digital Solutions on Diabetes Care"
Video 3 - "The Pivotal Role of Patient Engagement and Education in Achieving Optimal Diabetes Outcomes"
Video 2 - "Addressing Coexisting Conditions: Keys to Comprehensive Diabetes Care"
Video 1 - "The Influence of Social Determinants of Health on Diabetes Care and Outcomes"
Video 6 - "Failing to Reach Ideal Diabetes Care: Equitable Doesn’t Mean Equal"
Video 5 - "Revising Diabetes Outcome Measures"
Video 10 - "Managing Self Care"
Video 3 - "Embracing and Improving Access to Technology Tools"
Video 8 - "Demographic Differences That Impact Care"
Related Content
© 2024 MJH Life Sciences

All rights reserved.